Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
Biontech
https://www.proactiveinvestors.co.uk/companies/news/308611/scancell-research-collaboration-deal-with-european-biopharma-biontech-8611.html
I think they had screened 8 out of 24 Modi 1 TCRs in November.
As Ray reminded us,
Scancell have completed the process to create the viral vector which allows them to generate T Cells that can then be cloned and infused back into the patient.
However, they have found that the cloned T Cells do not have the necessary avidity to make them effective.
They haven't tested all of the possible T Cell epitopes so in Lindy's words "they may get lucky on any of those remaining epitopes"
So they are planning to repeat the process once they have human T Cells activated by Modi1.
One way of looking at this is that, if Modi1 is shown to be effective, then the Biontech collaboration becomes way more significant.
( in case any new investors are unaware)
BioNTech has followed up on its $270 million megaround by striking a deal with Scancell. The alliance gives BioNTech the chance to work with Scancell to discover and characterize T cell receptors (TCRs) and an option to form a license agreement covering the resulting therapeutics.
Mainz, Germany-based BioNTech made its name in mRNA but, supported by the $270 million round it wrapped up last week, it is expanding its R&D pipeline to other cancer-fighting modalities. The deal with Scancell gives BioNTech access to a platform that can support the broadening of the scope of its pipeline.
https://www.fiercebiotech.com/biotech/after-270m-round-biontech-pens-tcr-pact-scancell
The upshot is that Paston has worked at Immunocore since it was founded in 2008. Having started out as a senior research scientist, Paston went on to lead the T cell cloning and cell biology groups during her 11 years at the TCR specialist. Paston will now apply this experience to the emerging range of R&D tasks facing Scancell.
"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics,” Lindy Durrant
https://www.fiercebiotech.com/biotech/immunocore-lifer-leaves-to-head-research-at-tcr-rival-scancell
Adaptimmune released new data Wednesday showing their TCR therapy, known as afami-cel, shrunk the tumors of 13 of the 33 evaluable second-line sarcoma patients, including two patients whose tumors melted entirely
https://endpts.com/adaptimmune-gives-first-glimpse-at-pivotal-data-for-what-they-hope-will-be-first-approved-tcr/
https://www.einnews.com/pr_news/541332040/arthritis-monoclonal-antibodies-market-to-grow-at-a-rate-of-about-7-through-2025
https://www.youtube.com/watch?v=VEbic53pJ_A
https://markets.ft.com/data/announce/full?dockey=1323-14241913-6RENR3O1DG213ARBO9OLFCHRKD
FG2811 a new ultra-specific antibody with the ability to induce human stem memory T cell (TSCM) proliferation and differentiation. TSCM cells are a rare subset of white blood cells with the stem cell-like ability to self-renew and have capacity to differentiate into other T cell subsets that proliferate and accelerate anti-tumour immunity. Therefore, FG2811 has the potential to be utilised in vivo for cancer immunotherapy or to provide cells for CAR-T or TCR adoptive cell therapies.
Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales
http://www.globenewswire.com/news-release/2021/05/18/2231478/8060/en/Agenus-and-Bristol-Myers-Squibb-Announce-Exclusive-Global-License-for-Agenus-Anti-TIGIT-Bispecific-Antibody-Program.html
Coronavirus latest news: Government should have stalled May 17 reopening due to Indian variant, Sage member says
Indian variant may trigger local lockdowns
Restrictions similar to Tier 4 could be put in place under plans being reviewed by ministers
https://www.telegraph.co.uk/news/2021/05/17/indian-variant-may-trigger-local-lockdowns/
Yes I saw that Torquay.
It will be superb if Scancell can have some joy with their CV vaccine.
I am much more excited about the cancer work though.
#Singapore 28 airport workers become infected (esp w/ Indian variant), 19 of whom fully vaccinated w $MRNA or $BNTX: https://nytimes.com/2021/05/14/wor
https://www.nytimes.com/2021/05/14/world/asia/singapore-covid-restrictions.html
Bloomberg
@business
·
3h
JUST IN: Singapore is returning to lockdown mode for one month as virus cases rise, limiting groups to two people and making a planned travel bubble with Hong Kong unlikely
https://www.bloomberg.com/news/articles/2021-05-14/singapore-to-return-to-lockdown-mode-for-one-month-as-cases-rise?cmpid=socialflow-twitter-business&utm_source=twitter&utm_medium=social&utm_content=business&utm_campaign=socialflow-organic
Inovio’s vaccine takes the form of a DNA plasmid coding for the full length of the spike or ‘s’ glycoprotein antigen of SARS-CoV-2, the vaccine that causes COVID-19.
https://pharmaphorum.com/news/fda-slams-brakes-on-inovio-final-stage-covid-19-vaccine-trials/
Onovio`s market cap was $ 5 Billion .($30 ( now $6 ) in June 2020.
Illustrates that Scancell could go much higher.
https://www.fiercebiotech.com/biotech/inovio-shares-fall-as-astrazeneca-pares-down-partnership
AstraZeneca to pay Inovio Pharma $727 mln to produce cancer vaccine
https://www.proactiveinvestors.co.uk/companies/news/109837/astrazeneca-to-pay-inovio-pharma-727-mln-to-produce-cancer-vaccine-109837.html
Interesting cleanerworld.
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA® smart devices. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA.
INOVIO has created DNA-encoded monoclonal antibodies (dMAbs) that we believe overcome many of the limitations associated with conventional mAb technology
https://www.inovio.com/dna-medicines-technology/#science
There will be a SARS-CoV-3.’
https://stanfordmag.org/contents/of-viruses-and-vectors?sf143594792=1
Yes Chelsea, so much going for Scancell. When you listen to Lindy`s presentation, incredibly exciting. So much going on. I just think that such an incredible platform must be of interest to the big fish. Hopefully they will not be taken out too early.
https://youtu.be/VEbic53pJ_A?t=1321
.